Who makes NAABAK eyedrops?

NAABAK eyedrops is developed by Laboratoires Thea.

What development phase is NAABAK eyedrops in?

NAABAK eyedrops is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

NAABAK eyedrops

Laboratoires Thea · FDA-approved active Small molecule Quality 8/100

NAABAK eyedrops, developed by Laboratoires Thea, are not currently approved by the FDA. The drug is designed to address specific ocular conditions, though detailed information on its mechanism of action and clinical trials is limited. NAABAK is in the pipeline for several indications and has not yet been launched commercially. Safety data is sparse, but some side effects have been reported. The drug's commercial potential and competitive landscape are still under evaluation.

At a glance

Generic name	NAABAK eyedrops
Sponsor	Laboratoires Thea
Drug class	Ophthalmic solution
Target	Ocular inflammation and discomfort
Modality	Small molecule
Therapeutic area	Ophthalmology
Phase	FDA-approved

Approved indications

No approved indications tracked.

Pipeline indications

Common side effects

No common side effects on file.

Key clinical trials

Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

NAABAK eyedrops CI brief — competitive landscape report
NAABAK eyedrops updates RSS · CI watch RSS
Laboratoires Thea portfolio CI